Product image of Letromal (Letrozole) supplied by GNH India

Letromal

Active Ingredient:
Letrozole
Origin:
EU

Letromal (Letrozole)

Letrozole, the active ingredient in Letromal, is an aromatase inhibitor presented as an oral tablet for oral use. It is used to treat hormone receptor‑positive breast cancer in postmenopausal women by lowering estrogen production.
GNH India supplies Letromal as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Manufacturer / TM Owner

Williams & Halls Ehf

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole is an aromatase inhibitor indicated for hormone‑dependent breast cancer and related endocrine therapy pathways.

  • Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen‑driven tumor growth and helps prevent disease progression.
  • Adjuvant therapy after primary surgery: lowers the risk of cancer recurrence when used as part of postoperative treatment.
  • Metastatic breast cancer in postmenopausal patients: provides disease control by sustained estrogen suppression.

How It Works

  • Letrozole selectively and reversibly binds to the aromatase enzyme, inhibiting the conversion of androstenedione and testosterone to estrone and estradiol. This reduction in peripheral estrogen synthesis decreases circulating estrogen levels, limiting the proliferative stimulus on estrogen‑dependent tumor cells and thereby slowing cancer growth.

Side Effects

Letrozole may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Hot flashes: transient episodes of increased skin temperature.
  • Arthralgia: joint pain or stiffness.
  • Fatigue: general feeling of tiredness.
  • Nausea: mild to moderate upset stomach.
  • Headache: occasional mild headache.
  • Bone mineral density loss: gradual reduction in bone density.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clot formation in veins.
  • Severe liver injury: marked elevation of liver enzymes or hepatic failure.
  • Interstitial lung disease: inflammation of lung tissue.
  • Myocardial infarction: rare heart attack events.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Osteoporotic fractures: increased risk of bone fractures due to weakened bones.

Precautions & Warnings

Before initiating Letrozole therapy, consider the following safety measures.

  • Pregnancy risk: contraindicated in pregnancy; ensure effective contraception for women of childbearing potential.
  • Bone health: monitor bone mineral density and consider calcium/vitamin D supplementation.
  • Liver function: assess hepatic function periodically, especially in patients with pre‑existing liver disease.
  • Cardiovascular status: evaluate cardiovascular risk factors, as estrogen depletion may affect lipid profiles.
  • Drug interactions: review concomitant medications for potential interactions that may alter letrozole levels.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Letrozole can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP2A6 inhibitors (e.g., ketoconazole): may increase letrozole plasma concentrations.
  • Estrogen‑containing hormone therapy: antagonizes therapeutic effect.
  • Tamoxifen: concurrent use reduces efficacy of both agents.

Moderate Interactions (Monitor Closely)

  • Warfarin: may enhance anticoagulant effect; monitor INR.
  • Simvastatin: potential increase in statin levels; observe for myopathy.
  • SSRIs (e.g., fluoxetine): may affect hepatic metabolism; watch for altered letrozole exposure.

Frequently Asked Questions

Letromal contains letrozole, an aromatase inhibitor indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women. It is used to reduce estrogen levels, thereby slowing tumor growth and helping prevent disease recurrence.

Letrozole blocks the aromatase enzyme, which converts androgens into estrogen. By inhibiting this conversion, the drug lowers circulating estrogen concentrations, removing the hormonal stimulus that drives the growth of estrogen‑dependent breast cancer cells.

The dosage of Letromal is determined by the prescribing physician based on the patient’s clinical condition, treatment setting, and individual response. Patients should follow the dose and schedule provided by their healthcare professional.

Letromal is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding women, as it may pass into breast milk and affect the infant.

To order Letromal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Letromal (letrozole) is a third‑generation aromatase inhibitor with a high potency and a longer half‑life compared with earlier agents such as anastrozole. It is often preferred for its once‑daily dosing and demonstrated efficacy in both adjuvant and metastatic breast cancer settings.

Letromal tablets should be stored at ambient temperature below 25 °C, in the original container, protected from moisture and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged.

Letromal is taken orally, usually as a whole tablet with water. It is typically administered once daily, preferably at the same time each day, and can be taken with or without food as directed by the prescriber.

Serious risks include venous thromboembolism, severe liver injury, interstitial lung disease, myocardial infarction, and osteoporotic fractures. Patients should be monitored regularly for signs of these conditions, and any concerning symptoms should be reported promptly to a healthcare professional.

Letromal should not be used by pregnant women, individuals with known hypersensitivity to letrozole or any component of the formulation, and patients with severe liver impairment without careful monitoring. It is also contraindicated in women of childbearing potential who are not using effective contraception.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT